- Home
- MRDN vs GANX Comparison
MRDN vs GANX Comparison
Compare MRDN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRDN | GANX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 1200 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.7M | 78.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MRDN | GANX |
|---|---|---|
| Price | $7.69 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 19.0K | ★ 520.5K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | $16.30 | N/A |
| Revenue Next Year | $12.32 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.01 | $1.41 |
| 52 Week High | $10.48 | $4.34 |
Technical Indicators
Market Signals| Indicator | MRDN | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 59.30 | 38.95 |
| Support Level | $6.58 | $1.66 |
| Resistance Level | N/A | $2.11 |
| Average True Range (ATR) | 0.61 | 0.14 |
| MACD | 0.25 | -0.01 |
| Stochastic Oscillator | 92.03 | 10.21 |
Price Performance
Historical ComparisonAbout MRDN Meridian Holdings Inc. Common Stock
Meridian Holdings Inc is engaged in the online gaming and betting business, providing sports betting, online casino, and gaming operations across multiple jurisdictions in Europe, Africa, and Central and South America. The company has three reportable segments: MeridianBet Group, GMAG, and RKings & CFAC. The MeridianBet Group segment includes retail and online sports betting, casinos, and related gaming operations. The GMAG segment focuses on the resale of third-party gaming content, mainly serving customers in the Asia-Pacific region. The RKings & CFAC segment is involved in pay-to-enter prize competitions and trade promotions conducted in the United Kingdom and Australia. It generates the majority of its revenue from the MeridianBet Group segment.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.